Despite Advances, Many NSCLC Patients Go Untreated
A recent study found that over half of older adults with metastatic non-small cell lung cancer (NSCLC) did not receive systemic treatments despite advancements in therapies. The study revealed only modest increases in treatment rates from 2006 to 2021, with barriers such as access issues and referral practices potentially contributing to the lack of treatment. Researchers noted that younger patients and those with fewer comorbidities were more likely to receive therapy, highlighting disparities in care.
- ▪More than half of older adults with metastatic NSCLC never received systemic treatments.
- ▪The proportion of patients receiving treatment increased only slightly from 45% in 2006 to 48% in 2021.
- ▪Younger patients and those with fewer comorbidities were more likely to receive treatment.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/despite-advances-many-patients-nsclc-go-untreated-2026a1000g5f?src=rss |
| Publication time | Tue, 19 May 2026 05:01:43 EDT |
| Retrieval time | 2026-05-19T09:04:57.469Z |
| Last seen | 2026-05-19T09:04:57.469Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | GHzSWXly_2Sd |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
More than half of older adults with metastatic non-small cell lung cancer (NSCLC) never received systemic treatments, despite major advances in targeted therapies and more recent immunotherapy approaches, a recent population-based study found.Although the reasons remain unclear, including how many were too sick to be treated, the study suggests that some patients who appeared to be more likely candidates for treatment, given their younger age, fewer comorbidities, and survival past 90 days, still went untreated.Even as newer, more effective therapies became available, the degree of improvement in treatment rates remained “unimpressive,” the researchers said — a finding that “stunned” author Gerard A.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
